Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.96) per share. This is a 62.71 percent decrease over losses of $(0.59) per share from the same period last year.
Reported Late Monday, Nuvalent Announces Pricing Of ~$230M Public Offering Of 6,865,672 Shares Of Class A Common Stock Common Stock At A Price Of $33.50/Share
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its